{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:25:36Z","timestamp":1761611136162},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"S6","license":[{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to:<\/jats:p>\n                  <jats:p>Identify evidence-based options for treatment of patients with taxane-refractory breast cancer. Explain reasons for and limitations of patient preference for oral chemotherapy. Manage treatment toxicities of capecitabine. Discuss the mechanism of action of capecitabine.<\/jats:p>\n                  <jats:p>Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com<\/jats:p>\n                  <jats:p>The treatment of patients with metastatic breast cancer that has progressed despite previous anthracycline- and taxane-based therapy is a challenge for oncologists. Several agents, including vinorelbine, gemcitabine, pemetrexed, and particularly capecitabine, have been evaluated in this setting, either alone or in combination with other cytotoxic agents. The efficacy of many of these agents has not yet been clearly established in this setting, as the majority have been evaluated in a limited number of patients and predominantly in single-center trials. Furthermore, some agents with clinically meaningful activity are often associated with significant toxicity, particularly myelosuppression and neuropathy, while less toxic agents\/regimens often exchange improved tolerability for reduced activity.<\/jats:p>\n                  <jats:p>Capecitabine, an oral chemotherapeutic, is the agent that has been evaluated most extensively in this setting. A large, phase II trial (n = 163) conducted in North America demonstrated a disease control rate of 63%, including an objective response rate of 20%, median time to disease progression of 3.0 months, and median survival of approximately 1 year. Adverse events were typically mild to moderate in intensity and could be controlled with treatment interruption or, if necessary, dose adjustment to each individual's tolerable dose. Data recently reported from three other large trials in taxane-pretreated patients have revealed similar efficacy and tolerability. Together, these four trials show that single-agent capecitabine, in a population of 500 patients, consistently produced clinically meaningful efficacy, including median survival of approximately 1 year, with a favorable safety profile. Myelosuppression and alopecia were particularly rare. In addition, the oral administration of capecitabine, which enables convenient, patient-oriented therapy, makes it an attractive treatment for patients. Based primarily on the results of the pivotal trial, capecitabine received regulatory approval as treatment for anthracycline- and taxane-pretreated (paclitaxel-pretreated in the U.S.) metastatic breast cancer. In light of the confirmatory results of subsequent large trials, capecitabine is now considered a reference treatment in this setting, as no other agent has consistently demonstrated such high efficacy in as large a patient population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.7-suppl_6-20","type":"journal-article","created":{"date-parts":[[2004,8,25]],"date-time":"2004-08-25T16:29:36Z","timestamp":1093451376000},"page":"20-28","source":"Crossref","is-referenced-by-count":38,"title":["Single-Agent Capecitabine: A Reference Treatment for Taxane-Pretreated Metastatic Breast Cancer?"],"prefix":"10.1093","volume":"7","author":[{"given":"Andrew D.","family":"Seidman","sequence":"first","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center and Cornell University Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"O'Shaughnessy","sequence":"additional","affiliation":[{"name":"Baylor-Sammons Cancer Center and US Oncology, Dallas, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Misset","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Louis, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2002,12,1]]},"reference":[{"issue":"suppl 1","key":"2021122211541780300_R1","first-page":"S1","article-title":"Docetaxel: assessing a range of activity","volume":"12","author":"Aapro","year":"2001","journal-title":"Anticancer Drugs"},{"key":"2021122211541780300_R2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.1999.17.5.1413","article-title":"Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group","volume":"17","author":"Nabholtz","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122211541780300_R3","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0959-8049(99)00122-7","article-title":"Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group","volume":"35","author":"Sj\u00f6strom","year":"1999","journal-title":"Eur J Cancer"},{"issue":"suppl 4","key":"2021122211541780300_R4","first-page":"12","article-title":"Phase III study: Taxotere\u00ae (TXT) versus 5-fluorouracil plus navelbine (FUN) in patients with metastatic breast cancer (MBC) as 2nd-line chemotherapy (CT) preliminary results","volume":"9","author":"Monnier","year":"1998","journal-title":"Ann Oncol"},{"issue":"suppl 3","key":"2021122211541780300_R5","first-page":"S1","article-title":"Experience at the Istituto Nazionale Tumori with paclitaxel in combination with doxorubicin in women with untreated breast cancer","volume":"24","author":"Gianni","year":"1997","journal-title":"Semin Oncol"},{"issue":"suppl 3","key":"2021122211541780300_R6","first-page":"S13","article-title":"Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer","volume":"24","author":"L\u00fcck","year":"1997","journal-title":"Semin Oncol"},{"key":"2021122211541780300_R7","first-page":"127a","article-title":"A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC","volume":"18","author":"Nabholtz","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122211541780300_R8","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1200\/JCO.2002.11.005","article-title":"Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase II trial","volume":"20","author":"Biganzoli","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122211541780300_R9","first-page":"35a","article-title":"Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC)","volume":"21","author":"Mackey","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122211541780300_R10","first-page":"1541","volume-title":"Cancer: Principles and Practices of Oncology","author":"Dickson","year":"1997","edition":"Fifth Edition"},{"key":"2021122211541780300_R11","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.1998.16.10.3362","article-title":"A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer","volume":"16","author":"Valero","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122211541780300_R12","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1200\/JCO.1996.14.6.1877","article-title":"Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer","volume":"14","author":"Seidman","year":"1996","journal-title":"J Clin Oncol"},{"key":"2021122211541780300_R13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0959-8049(99)00219-1","article-title":"Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer","volume":"36","author":"Udom","year":"2000","journal-title":"Eur J Cancer"},{"key":"2021122211541780300_R14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s002800050551","article-title":"Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel\u2014a phase II study","volume":"39","author":"Fazeny","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122211541780300_R15","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/1097-0142(20011101)92:9<2267::AID-CNCR1572>3.0.CO;2-Q","article-title":"Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma","volume":"92","author":"Zelek","year":"2001","journal-title":"Cancer"},{"key":"2021122211541780300_R16","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.1997.15.4.1395","article-title":"Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer","volume":"15","author":"Livingston","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122211541780300_R17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/A:1010679127390","article-title":"Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing on both an anthracycline and a taxane","volume":"66","author":"Smorenburg","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"2021122211541780300_R18","first-page":"95","article-title":"Can patients with metastatic breast cancer (MBC) pretreated with cyclophosphamide (C), anthracyclines (A) or taxol (tax) respond to infusions of 5-FU (FUI)? Rationale for FUI-containing chemotherapy (CT) regimens","volume":"46","author":"Ragaz","year":"1997","journal-title":"Breast Cancer Res Treat"},{"key":"2021122211541780300_R19","first-page":"130a","article-title":"Pemetrexed disodium (Alimta, LY231514, MTA) in locally advanced or metastatic breast cancer (MBC) patients (Pts) with prior anthracycline or anthracenedione and taxane treatment: phase II study","volume":"19","author":"Theodoulou","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122211541780300_R20","first-page":"30a","article-title":"Phase III trial of pegylated liposomal doxorubicin (Caelyx\/doxil) for the treatment of patients with advanced breast cancer who have failed a prior taxane-containing chemotherapy regimen","volume":"20","author":"Keller","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 4","key":"2021122211541780300_R21","first-page":"24a","article-title":"Vinorelbine-5-fluorouracil combination as second line chemotherapy in metastatic breast cancer (MBC) after anthracycline-taxanes combination (AT)","volume":"11","author":"Girre","year":"2000","journal-title":"Ann Oncol"},{"key":"2021122211541780300_R22","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1200\/JCO.2002.06.164","article-title":"Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients","volume":"20","author":"Zelek","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122211541780300_R23","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1054\/bjoc.2001.2001","article-title":"Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes","volume":"85","author":"Kalbakis","year":"2001","journal-title":"Br J Cancer"},{"issue":"suppl 6","key":"2021122211541780300_R24","first-page":"S196a","article-title":"Salvage treatment with irinotecan and gemcitabine in breast cancer patients pretreated with taxanes and anthracyclines: a multicenter phase II study","volume":"37","author":"Agelaki","year":"2001","journal-title":"Eur J Cancer"},{"issue":"suppl 10","key":"2021122211541780300_R25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0093-7754(01)80009-9","article-title":"Gemcitabine\/cyclophosphamide\/5-fluorouracil\/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I\/II study","volume":"28","author":"Frasci","year":"2001","journal-title":"Semin Oncol"},{"key":"2021122211541780300_R26","first-page":"111a","article-title":"Prospective phase II study of weekly cisplatin-gemcitabine in refractory metastatic breast cancer (RM-BC)","volume":"19","author":"Chaudhry","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122211541780300_R27","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1023\/A:1008361711049","article-title":"Gemcitabine and vinorelbine as second-line treatment in patents with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group","volume":"11","author":"Nicolaides","year":"2000","journal-title":"Ann Oncol"},{"key":"2021122211541780300_R28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1023\/A:1008348704373","article-title":"Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study","volume":"11","author":"Valenza","year":"2000","journal-title":"Ann Oncol"},{"key":"2021122211541780300_R29","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1023\/A:1012249630074","article-title":"A phase II study of oral eniluracil\/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer","volume":"12","author":"Skovsgaard","year":"2001","journal-title":"Ann Oncol"},{"key":"2021122211541780300_R30","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.2002.20.4.987","article-title":"Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline-and taxane-resistant advanced breast cancer","volume":"20","author":"Rivera","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122211541780300_R31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1054\/brst.2000.0170","article-title":"Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer","volume":"9","author":"Brodowicz","year":"2000","journal-title":"The Breast"},{"key":"2021122211541780300_R32","first-page":"51b","article-title":"Gemcitabine (G) in pretreated breast cancer (BC)","volume":"20","author":"Valerio","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122211541780300_R33","first-page":"57b","article-title":"Efficacy of gemcitabine as a salvage treatment in breast cancer patients refractory to anthracycline and paclitaxel based regimen","volume":"21","author":"Rha","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122211541780300_R34","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/0277-9536(92)90053-S","article-title":"A study of quality of life in cancer patients receiving palliative chemotherapy","volume":"35","author":"Payne","year":"1992","journal-title":"Soc Sci Med"},{"key":"2021122211541780300_R35","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","article-title":"Patient preferences for oral versus intravenous palliative chemotherapy","volume":"15","author":"Liu","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122211541780300_R36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0959-8049(01)00371-9","article-title":"Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer","volume":"38","author":"Borner","year":"2002","journal-title":"Eur J Cancer"},{"key":"2021122211541780300_R37","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer","volume":"17","author":"Blum","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122211541780300_R38","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A","article-title":"Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients","volume":"92","author":"Blum","year":"2001","journal-title":"Cancer"},{"key":"2021122211541780300_R39","first-page":"285a","article-title":"Phase II study of capecitabine (Xeloda\u00ae) in pts with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes","volume":"69","author":"Fumoleau","year":"2001","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 6","key":"2021122211541780300_R40","doi-asserted-by":"crossref","first-page":"S191a","DOI":"10.1016\/S0959-8049(01)81191-6","article-title":"Capecitabine: the new standard in metastatic breast cancer failing anthracycline and taxane-containing chemotherapy? Mature results of a large multicenter phase II trial","volume":"37","author":"Reichardt","year":"2001","journal-title":"Eur J Cancer"},{"issue":"suppl 6","key":"2021122211541780300_R41","doi-asserted-by":"crossref","first-page":"S190a","DOI":"10.1016\/S0959-8049(01)81185-0","article-title":"Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated mbc: updated results and analysis of dose modification","volume":"37","author":"Blum","year":"2001","journal-title":"Eur J Cancer"},{"key":"2021122211541780300_R42","doi-asserted-by":"crossref","first-page":"798","DOI":"10.7326\/0003-4819-101-6-798","article-title":"Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome","volume":"101","author":"Lokich","year":"1984","journal-title":"Ann Intern Med"},{"key":"2021122211541780300_R43","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/(SICI)1097-0142(19980301)82:5<965::AID-CNCR23>3.0.CO;2-Y","article-title":"Hand-foot syndrome following prolonged infusion of high doses of vinorelbine","volume":"82","author":"Hoff","year":"1998","journal-title":"Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.7-suppl_6-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.7-suppl_6-20","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/7\/S6\/20\/41838942\/oncolo_7_s6_20.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/7\/S6\/20\/41838942\/oncolo_7_s6_20.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T18:46:53Z","timestamp":1640198813000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/7\/S6\/20\/6386747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12,1]]},"references-count":43,"journal-issue":{"issue":"S6","published-online":{"date-parts":[[2002,12,1]]},"published-print":{"date-parts":[[2002,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.7-suppl_6-20","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2002,12,1]]},"published":{"date-parts":[[2002,12,1]]}}}